In summary, we uncovered that genetic alterations in PIK3CA, PTEN, ERBB3, and PI3K/AKT pathway could be novel predictive biomarkers in patients with cervical cancer treated with PD-1 inhibitor combination therapy. Here, ERBB3 is linked to cervical carcinoma.